| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Jan―15 |
Efficacy and Safety of Antimalarial as Repurposing Drug for COVID-19 Following Retraction of Chloroquine and Hydroxychloroquine |
Irma Latarissa, Miski Khairinisa, Ghina Iftinan, Anna Meiliana, Ida Sormin, Melisa Barliana, Keri Lestari |
| 2 |
[GO] |
2024―Jan―04 |
Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review |
Paula Andrea Velásquez, Juan Hernandez, Elkin Galeano, Jaime Hincapié-García, María Rugeles, Wildeman Zapata-Builes |
| 3 |
[GO] |
2022―Apr―04 |
Evaluating Pharmacists’ Pharmacological Knowledge and Views Regarding Pfizer-BioNTech COVID-19 Vaccine in Saudi Arabia |
Nasser Alorfi, Ahmed Ashour |
| 4 |
[GO] |
2021―Dez―06 |
Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review |
Irma Rahayu Latarissa, Melisa Intan Barliana, Anna Meiliana, Keri Lestari |
| 5 |
[GO] |
2021―Sep―29 |
Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19 |
Prasan Kumar Panda, Budha O Singh, Bikram Moirangthem, Yogesh Arvind Bahurupi, Sarama Saha, Girraj Saini, et al. (+7) Minakshi Dhar, Mukesh Bairwa, Venkatesh Srinivasa Pai Pai, Ankit Agarwal, Girish Sindhwani, Shailendra Handu, Ravi Kant |
| 6 |
[GO] |
2020―Dez―13 |
An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease |
Tafere Mulaw Belete |
| 7 |
[GO] |
2020―Aug―20 |
Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan |
Yasuhiro Kamioka, Shota Kashiwagura, Masafumi Seki |
| 8 |
[GO] |
2020―Aug―17 |
Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety |
Sitaram Khadka, Dhan Bahadur Shrestha, Pravash Budhathoki, Era Rawal |
